<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03254667</url>
  </required_header>
  <id_info>
    <org_study_id>V01-BROA-402</org_study_id>
    <nct_id>NCT03254667</nct_id>
  </id_info>
  <brief_title>LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis</brief_title>
  <official_title>Prospective, Observational Study Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with
      Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with
      Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis Who Are
      Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2018</start_date>
  <completion_date type="Anticipated">November 2031</completion_date>
  <primary_completion_date type="Anticipated">November 10, 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>8 Years</target_duration>
  <primary_outcome>
    <measure>Assess the incidence of malignancy</measure>
    <time_frame>8 years</time_frame>
    <description>Assess the incidence of malignancy, excluding non-melanoma skin cancer (NMSC), in adult psoriasis subjects exposed to brodalumab in the course of actual clinical care compared to non-IL-17-inhibitor biologic medications used to treat psoriasis.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Brodalumad exposed</arm_group_label>
    <description>1500 subjects exposes to brodalumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Subjects</arm_group_label>
    <description>2000 comparator subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Brodalumab</intervention_name>
    <description>Brodalumab</description>
    <arm_group_label>Brodalumad exposed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator Drug (non-biologic IL-17 inhibitors)</intervention_name>
    <description>Comparator subjects treated with non-biologic IL-17 inhibitors</description>
    <arm_group_label>Comparator Subjects</arm_group_label>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Neutrophil count
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study population consisting of 1500 subjects treated with Brodalumab, and 2000 comparator
        subjects being treated with a non-biologic IL-17 inhibitor drug.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis and main criteria for inclusion: a subject must have moderate to severe
             psoriasis diagnosed by a dermatologist

          2. Must be at least 18 years of age or older

          3. Started on or switched to a systemic psoriasis treatment within the previous 12
             months. FDA-approved biologic treatments and select non-biologic treatments (eg,
             methotrexate, cyclosporine, or apremilast only) are permitted.

        Exclusion Criteria:

          1. The subject is unable or unwilling to provide informed consent to participate in the
             registry.

          2. The subject is participating or planning to participate in a clinical trial with a
             non-marketed or marketed investigational drug (i.e. Phase I-IV drug trial).

          3. The subject is restarting the eligible medication less than 12 months since receiving
             the last dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Lindsey Mathew</last_name>
    <role>Study Director</role>
    <affiliation>Valeant Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lindsey Mathew</last_name>
    <phone>9085413279</phone>
    <email>lindsey.mathew@valeant.com</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2017</study_first_submitted>
  <study_first_submitted_qc>August 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2017</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

